Skip to main content

Table 2 Reported cases in Japan of perforation in the gastrointestinal tract caused by MTX-associated lymphoproliferative disorder

From: Cessation of methotrexate and a small intestinal resection provide a good clinical course for a patient with a jejunum perforation induced by a methotrexate-associated lymphoproliferative disorder: a case report

Case

Year

Age

Sex

Organ

CD20

EBV

Diagnosis

Operation

Chemotherapy

Prognosis

1

1995

73

M

Ileum

Positive

Negative

DLBCL

Rt. hemicolectomy

No

Dead

2

2004

87

F

Ileum

Positive

DLBCL

Partial resection

No

Alive

3

2006

63

M

Ileum

Positive

Positive

DLBCL

Ileo-cecum resection

No

Alive

4

2011

82

F

Ileum

Positive

Positive

DLBCL

Ileo-cecum resection

Yesa

Alive

5

2016

70

F

Ileum

Positive

Positive

DLBCL

Rt. hemicolectomy

No

Alive

6

2017

77

F

Ileum

Positive

Negative

DLBCL

Partial resection

No

Alive

7

2018

66

F

Ileum

Positive

Positive

DLBCL

Partial resection

No

Alive

8

2020

62

M

Jejunum

Positive

Positive

DLBCL

Partial resection

No

Alive

Present case

2020

81

F

Jejunum

Positive

Positive

EBVMCU

Partial resection

No

Alive

  1. CD20 cluster of differentiation 20, EBV Epstein–Barr virus, DLBCL diffuse large B cell lymphoma, EBVMCU Epstein–Barr virus-positive mucocutaneous ulcer, Rt. hemicolectomy right hemicolectomy
  2. aR-THP-COP 5course: rituximab (R), tetrahydropyranyl adriamycin (THP), cyclophosphamide (CPA), vincristine (VCR), and prednisolone (PSL)